https://scholars.lib.ntu.edu.tw/handle/123456789/624333
Title: | Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan | Authors: | SHANG-GIN WU Chiang, Chi-Lu Wang, Chin-Chou Hung, Jen-Yu Hsia, Te-Chun Kuo, Chih-Hsi JIN-YUAN SHIH |
Keywords: | Atezolizumab; Epidermal growth factor receptor mutation; Immune checkpoint inhibitor; Non-small-cell lung cancer; Osimertinib; Tyrosine kinase inhibitor | Issue Date: | 2022 | Publisher: | IVYSPRING INT PUBL | Journal Volume: | 13 | Journal Issue: | 9 | Start page/Pages: | 2922 | Source: | Journal of Cancer | Abstract: | Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small-cell lung cancer (NSCLC). We assessed the clinical prognostic factors in NSCLC patients receiving atezolizumab as a second- or later-line (2L+) treatment. Data were retrospectively collected for NSCLC patients treated with atezolizumab from July 2017 to June 2019 at six medical centers in Taiwan. Clinical characteristics, treatment course and responses of patients were recorded. A total of 128 NSCLC patients received 2L+ atezolizumab, and the outcomes included a response rate of 10.2%, median progression-free survival (mPFS) of 3.5 months, and median overall survival (mOS) of 10.7 months. Eleven patients who had received osimertinib treatment before atezolizumab had a shorter mPFS (2.3 versus 3.5 months; p = 0.002) and mOS (4.8 versus 11.2 months; p < 0.001) than those without prior osimertinib treatment. Even for the subgroup of patients with EGFR-mutant non-squamous NSCLC, prior osimertinib was still associated with shorter PFS (2.3 versus 4.1 months; p = 0.006) and OS (4.8 versus 11.7 months; p < 0.001). Multivariate analysis revealed that prior osimertinib treatment correlated with not only shorter PFS (hazard ratio [HR]: 2.94; 95% confidence interval [CI], 1.34-6.47; p = 0.007) but also shorter OS (HR, 3.55; 95% CI, 1.57-8.03; p = 0.002). Patients with prior ICIs treatment (HR, 3.18; p = 0.002) or poor performance status (HR, 2.70; p = 0.001) had shorter OS. In conclusion, osimertinib treatment before atezolizumab therapy was associated with a shorter PFS and a poor prognosis in NSCLC patients in real-world settings. Further studies with larger sample sizes are needed to validate these observations. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/624333 | ISSN: | 1837-9664 | DOI: | 10.7150/jca.74617 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.